150
Participants
Start Date
July 18, 2024
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
NVL-330
Oral Tablet of NVL-330
RECRUITING
North Shore Health Hub, Saint Leonards
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Georgetown University Medical Center, Washington D.C.
RECRUITING
Sibley Memorial Hospital, Washington D.C.
RECRUITING
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Medical Center, Baltimore
RECRUITING
NEXT Virginia, Fairfax
RECRUITING
Sylvester Comprehensive Cancer Center, Miami
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
OSU Brain and Spine Hospital, Columbus
RECRUITING
Henry Ford Cancer Center, Detroit
RECRUITING
Washington University, St Louis
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Sarah Cannon Research Institute at HealthONE, Denver
RECRUITING
City of Hope - Lennar, Irvine
RECRUITING
Stanford Cancer Institute, Stanford
RECRUITING
University of California, Davis Comprehensive Cancer Center, Sacramento
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Chris O'Brien Lifehouse, Camperdown
RECRUITING
Cross Cancer Institute, Edmonton
RECRUITING
Princess Margaret Cancer Center - University Health Network, Toronto
Lead Sponsor
Nuvalent Inc.
INDUSTRY